好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Radiomics-based Unsupervised Clustering of Acute Multiple Sclerosis Lesions
Multiple Sclerosis
P10 - Poster Session 10 (8:00 AM-9:00 AM)
3-015

To leverage radiomics and machine learning to identify clusters of focal acute MS lesions exhibiting similar spatial and/or textural patterns on conventional cross-sectional (pre- and post-contrast) T1-weighted, T2-weighted, PD-weighted and FLAIR brain MRIs.

Multiple sclerosis (MS) lesions exhibit substantial heterogeneity in terms of underlying pathology, anatomic location, and longitudinal evolution. Conventional MRI is sensitive to some aspects of lesion heterogeneity. Unsupervised clustering approaches may identify subtypes of acute MS lesions with specific pathologic features and help improve disease characterization and prognostication.

Brain MRIs from the ADVANCE trial (1,512 patients with relapsing-remitting MS, NCT00906399) were retrospectively analysed. For each scan, focal acute (gadolinium-enhancing and/or new or substantially enlarging) T2 lesions (N=3058) were identified in the white matter (WM). Each lesion was represented via its center of mass in standard ICBM-152 space and radiomics-based textural properties. Similar lesions were grouped together via k-means clustering, applied separately across the spatial and each sequence-specific textural domain. Cluster count was optimized based on the silhouette score, Davies-Bouldin index and Variance Ratio Criterion.

Optimal clustering quality resulted in 8 prototypical WM sites of lesion emergence, 3 prototypical textural patterns on each of post-contrast T1-, PD-weighted and FLAIR MRI and 5 patterns on each of pre-contrast T1- and T2-weighted MRI. Statistically significant cross-sectional associations were found between the occurrence of these lesion subtypes and patient age, sex, years since disease onset and EDSS score, via logistic regression analysis (p < 0.05).

Specific spatial and textural patterns of acute MS lesions were identified using unsupervised clustering. Further work will evaluate the clinical relevance of identified acute MS lesion patterns towards predicting clinical and MRI endpoints of disease progression. The longitudinal dynamics of each lesion pattern will be investigated via measurements of future lesion repair or transition towards chronic active/inactive lesion states.

Authors/Disclosures
Bastien C. Caba (Biogen Canada)
PRESENTER
Mr. Caba has received personal compensation for serving as an employee of Therapanacea. Mr. Caba has received personal compensation for serving as an employee of Biogen. Mr. Caba has received personal compensation in the range of $50,000-$99,999 for serving as a Research Engineer with Therapanacea. Mr. Caba has received personal compensation in the range of $100,000-$499,999 for serving as a Scientist II, ML/AI with Biogen.
Arie Gafson, MD, PhD (Biogen) Dr. Gafson has stock in Biogen.
Despoina Ioannidou, PhD (Therapanacea) Dr. Ioannidou has received personal compensation for serving as an employee of Therapanacea.
Phoebe Jiang, PhD Dr. Jiang has received personal compensation for serving as an employee of Biogen. Dr. Jiang has stock in Biogen.
Elizabeth Fisher Elizabeth Fisher has received personal compensation for serving as an employee of Biogen. Elizabeth Fisher has stock in Biogen. Elizabeth Fisher has received intellectual property interests from a discovery or technology relating to health care.
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ) Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Clario.
Colm Elliott (NeuroRx Research) Colm Elliott has received personal compensation for serving as an employee of NeuroRx Research.
No disclosure on file
Shibeshih Belachew, MD Dr. Belachew has received personal compensation for serving as an employee of Biogen Inc. Dr. Belachew has received stock or an ownership interest from Biogen Inc.